Nanofilament immunotherapy induces potent antitumor vaccine responses.

ABSTRACT:

Background

Checkpoint inhibitors revolutionized cancer treatment by potentiating antitumor immune responses. However, many patients do not respond to these therapies, often due to the lack of a pre-existing immune response against cancer cells. Developing immunotherapies that promote cancer-cell antigen recognition, and the initiation of antitumor immune responses could thus improve response rates.

Methods

We established multimodal nanofilament immunotherapy as an antigen-agnostic in situ cancer vaccine modality. Through genetic engineering of the M13 bacteriophage, nanofilaments displaying combinations of therapeutic agents were generated to guide immune recognition and response against cancer cells. TAT003 is a multimodal nanofilament combining the natural adjuvant propert

SUBMITTER: Neil K 

PROVIDER: S-EPMC12557779 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature